Innovative Technologies in Social

Beyond the Pill – The Future of LipidLowering Therapy: A 2026 Review of Novel Lipid-Lowering Agents

These agents have expanded treatment options for patients with familial dyslipidaemia, severe hypertriglyceridaemia, and persistent residual cardiovascular risk while paving the way for precision medicine.

Expert Opinion on the Use of Inclisiran in Post-Acute Coronary Syndrome Patients in Indonesia

Elevated low-density lipoprotein cholesterol (LDL-C) levels are an independent risk factor for the progression of atherosclerotic cardiovascular disease (ASCVD). Achieving substantial LDL-C reduction is recognized as a primary therapeutic goal, particularly for those at the highest risk of future cardiovascular events....

New pharmacological interventions for lipoprotein(a) reduction and prevention of cardiovascular events: A systematic review

INTRODUCTION: Cardiovascular diseases remain the leading cause of global mortality, with atherosclerosis as a central mechanism. Lipoprotein(a) [Lp(a)] is an independent and highly atherogenic risk factor associated with vascular inflammation and thrombosis. Statins do not reduce Lp(a) levels and may even increase them...

Innovative Technologies in Social

Residual cardiovascular risk beyond LDL-cholesterol control: what remains unaddressed?

Statins, ezetimibe, and PCSK9 inhibitors have enabled LDL-cholesterol to be lowered to levels previously thought very hard to achieve. However, even after achieving low levels, some patients continued to have cardiovascular events, a phenomenon known as residual cardiovascular risk. This phenomenon indicates the comple...

Current, novel and emerging lipid-lowering therapies in pediatric familial hypercholesterolemia.

As therapeutic options expand and agents with greater LDL-C reductions become available, personalized treatment strategies will become increasingly important to achieve LDL-C targets and may ultimately shift from stepwise intensification approaches toward early intensive treatment.